Stereotactic radiosurgery for skull-base meningiomas: location-specific treatment strategies and outcomes
Article information
Abstract
Skull-base meningiomas are challenging because of their proximity to critical neurovascular structures. This systematic review evaluated the location-specific role of stereotactic radiosurgery (SRS), focusing on patient selection, treatment strategy, tumor control, functional outcomes, and complications. PubMed/MEDLINE was searched from inception through July 11, 2026. Eligible studies included adults with skull-base meningiomas treated with SRS, hypofractionated or multisession radiosurgery, staged radiosurgery, or stereotactic radiotherapy and reporting location-specific outcomes. Study selection followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidance. Methodological quality was assessed with design-appropriate tools, and findings were synthesized narratively because of substantial heterogeneity. Of 771 identified records, 275 underwent detailed eligibility assessment and 28 were included. Evidence was strongest for cavernous sinus meningiomas, supporting primary or postoperative SRS. Favorable outcomes were also reported for selected petroclival, cerebellopontine angle, posterior fossa, tentorial, olfactory groove, and foramen magnum meningiomas. For perioptic, tuberculum sellae, and anterior clinoidal tumors, suitability depended on respecting optic pathway tolerance. Hypofractionated or fractionated treatment expanded applicability to selected larger tumors or tumors contacting critical structures. SRS provides durable tumor control with acceptable morbidity when individualized according to location, tumor volume, neurological status, and proximity to critical structures.
INTRODUCTION
Skull-base meningiomas remain among the most challenging intracranial tumors to manage because of their close relationship with the cranial nerves, major vessels, optic apparatus, brainstem, and pituitary–hypothalamic structures. Although most are histologically benign, complete surgical removal may be difficult and can result in substantial neurological morbidity. Accordingly, treatment goals have increasingly shifted from radical resection toward durable tumor control with preservation of neurological function [1,2].
Microsurgery remains essential for large tumors causing significant mass effect, hydrocephalus, progressive visual deterioration, or brainstem compression. However, in patients for whom complete resection carries an unacceptable risk, stereotactic radiosurgery (SRS) provides an important alternative. SRS may be used as primary treatment for selected small- to moderate-sized tumors, as adjuvant treatment for residual disease after function-preserving subtotal resection, or as salvage treatment for recurrent tumors [1-3].
The suitability of SRS varies according to tumor location, volume, growth pattern, neurological status, and proximity to critical structures. Cavernous sinus meningiomas are frequently treated with SRS because of the high morbidity of aggressive resection, whereas petroclival, perioptic, or foramen magnum tumors may require different strategies depending on brainstem, optic pathway, or spinal cord compression. Larger tumors or lesions broadly contacting critical structures may also require hypofractionated or fractionated treatment [3-6].
Although favorable outcomes after SRS have been reported, the available evidence is heterogeneous and often limited to individual anatomical subgroups. This systematic review therefore evaluated the role of SRS for skull-base meningiomas according to anatomical location, with emphasis on patient selection, treatment technique, tumor control, functional outcomes, and treatment-related complications.
METHODS
Study design and literature search
We conducted a systematic literature review with narrative evidence synthesis to evaluate the location-specific use of SRS for skull-base meningiomas. The review focused on patient selection, tumor characteristics, radiosurgical techniques, radiological tumor control, neurological and functional outcomes, and treatment-related adverse events according to anatomical tumor location. The review process and reporting were structured in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement.
PubMed/MEDLINE was searched from database inception through July 11, 2026. The search strategy combined controlled vocabulary and free-text terms related to meningioma, skull-base anatomical locations, SRS, Gamma Knife radiosurgery, CyberKnife, linear accelerator–based radiosurgery, hypofractionated radiosurgery, and stereotactic radiotherapy. Anatomical search terms included the cavernous sinus, petroclival and clival regions, petrous region, cerebellopontine angle, posterior fossa, perioptic and parasellar regions, tuberculum sellae, planum sphenoidale, anterior clinoid, medial sphenoid wing, tentorium, olfactory groove, Meckel’s cave, foramen magnum, and jugular foramen. Reference lists of relevant original studies, systematic reviews, meta-analyses, and practice guidelines were additionally examined to verify the completeness of the location-specific literature.
AI-assisted tools were used to organize the retrieved records and support preliminary title and abstract screening. The AI-assisted screening results were used as decision-support information and did not determine final study inclusion. Publications considered potentially eligible underwent detailed full-text assessment. The final eligibility of candidate publications and the final included-study list were independently verified by two reviewers (Y.Y. and M.H.L.). Any disagreements were resolved through discussion and consensus. Before the final synthesis, the PubMed search results and included-study list were cross-checked using publication titles, author groups, participating institutions, recruitment periods, sample sizes, and PubMed identifiers. This process was also used to identify updated publications and potentially overlapping patient cohorts. The complete PubMed search strategy is provided in the Supplementary Methods.
The PubMed/MEDLINE search identified 771 records. No duplicate records were identified within the exported dataset. After initial title and abstract screening, 496 records were excluded, and 275 publications underwent detailed eligibility assessment. Of these, 247 were excluded because of ineligible study design, lack of separately extractable location-specific outcomes, overlapping, superseded, or less complete cohorts, absence of relevant clinical outcomes, or an ineligible tumor population. A total of 28 publications were included in the final qualitative synthesis. The study-selection process is summarized in Fig. 1.
Eligibility and study selection
Studies were eligible when they evaluated adult patients with radiologically presumed or histologically confirmed skull-base meningiomas treated with single-fraction SRS, hypofractionated or multisession radiosurgery, staged radiosurgery, or stereotactic radiotherapy. Eligible publications were required to provide outcomes for a specific skull-base location or for a clearly defined skull-base cohort.
Outcomes of interest included radiological tumor regression, stability, or progression; local tumor control; progression-free survival; cranial nerve function; visual and hearing outcomes; neurological deterioration; treatment-related adverse events; and the requirement for additional treatment.
Original clinical studies generally included at least 10 relevant patients and reported a mean or median follow-up duration of at least 12 months. Smaller studies were considered for uncommon anatomical locations when they represented the best available location-specific evidence. Systematic reviews, meta-analyses, and practice guidelines were included when they provided relevant location-specific evidence or clinically important contextual information. These secondary publications were not considered independent patient cohorts when interpreting treatment outcomes.
Case reports, small case series without meaningful clinical outcome data, technical reports without adequate follow-up, conference abstracts, editorials, and studies in which skull-base outcomes could not be separately extracted were excluded. Studies evaluating only conventional external-beam radiotherapy, cohorts predominantly composed of World Health Organization grade 2 or 3 meningiomas without separately reported benign-tumor outcomes, spinal or extracranial meningiomas, and studies without adequate clinical or radiological follow-up were also excluded.
Management of overlapping cohorts
Potentially overlapping cohorts were identified by comparing participating institutions, author groups, recruitment periods, sample sizes, treatment characteristics, and baseline patient and tumor features.
When a later publication explicitly updated or expanded an earlier patient cohort, the updated report was selected as the principal publication, and the earlier report was excluded unless it provided additional nonduplicated outcomes. For other potentially overlapping publications, the report with the largest cohort, longest follow-up, or most complete location-specific data was selected as the principal study.
Secondary publications were retained only when they provided additional nonduplicated information, such as cranial nerve–specific outcomes, visual or hearing outcomes, volumetric tumor response, dose–volume relationships, fractionated-treatment results, or extended follow-up. Overlapping publications were not interpreted as independent patient cohorts when summarizing tumor-control or adverse-event outcomes.
Data extraction and anatomical classification
Data were extracted using a standardized data-collection form. Extracted publication-level variables included the first author, publication year, study design, participating institutions, recruitment period, number of patients and treated tumors, and duration of follow-up.
Patient- and tumor-related variables included age, sex, anatomical location, histological diagnosis and World Health Organization grade when available, primary, postoperative adjuvant, or postresection salvage treatment setting, previous surgery or radiotherapy, tumor volume, maximum tumor diameter, pre-existing neurological deficits, and the presence of optic pathway, brainstem, cerebellar, temporal lobe, medullary, or upper cervical spinal cord compression.
Treatment-related variables included the radiosurgical platform, prescription marginal dose, maximum dose, prescription isodose, number of fractions, and reported doses to adjacent organs at risk, including the optic apparatus, brainstem, cochlea, pituitary gland, medulla, and spinal cord.
Outcome variables included radiological tumor regression, stability, or progression; local tumor control; progression-free survival; outcomes according to primary versus postoperative or salvage treatment when reported; cranial nerve improvement, stability, or deterioration; visual and hearing outcomes; peritumoral edema; radiation necrosis; hypopituitarism; other adverse radiation effects; and the requirement for repeat SRS, additional radiotherapy, or salvage surgery.
When both tumor-level and patient-level results were available, tumor-level data were used for radiological outcomes, whereas patient-level data were used for neurological and treatment-related adverse-event outcomes whenever possible.
The included publications were classified according to the principal dural attachment or predominant anatomical compartment of the tumor. The anatomical categories comprised cavernous sinus, petroclival and clival, cerebellopontine angle and posterior petrous, posterior fossa, perioptic, tuberculum sellae and planum sphenoidale, anterior clinoid and medial sphenoid wing, tentorial and tentorial incisural, olfactory groove, foramen magnum, and jugular foramen meningiomas. Studies evaluating large or extensive skull-base meningiomas treated with hypofractionated, fractionated, multisession, or staged stereotactic techniques were analyzed separately.
Methodological quality assessment
Methodological quality was assessed using appraisal tools appropriate to the design of each publication. Original single-arm observational studies and case series were evaluated using the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Comparative observational studies were assessed using the Newcastle–Ottawa Scale when applicable. Systematic reviews and meta-analyses were evaluated using AMSTAR 2. Practice guidelines were used primarily to contextualize the findings and were not evaluated together with original clinical studies using the Joanna Briggs Institute checklist.
The appraisal findings were used to inform the interpretation and relative weighting of the evidence rather than as an absolute exclusion criterion, because high-quality location-specific evidence was limited for several uncommon skull-base meningioma subgroups. Methodological limitations were considered when evaluating the reliability, generalizability, and clinical applicability of individual publications.
Evidence synthesis
The 28 included publications were synthesized narratively according to anatomical location. For each location, the synthesis evaluated the clinical settings in which primary, postoperative, or salvage SRS was used; tumor volumes and anatomical characteristics represented in the literature; commonly used prescription doses and fractionation strategies; tumor-control and progression-free survival outcomes; cranial nerve and other functional outcomes; location-specific organs at risk; and circumstances in which fractionated treatment or surgical decompression was favored over single-fraction SRS.
Formal quantitative pooling was not performed because of substantial heterogeneity in study design, anatomical classification, previous treatment, tumor volume, radiosurgical platform, prescription dose, follow-up duration, and outcome definitions. Greater interpretive weight was assigned to multicenter studies, larger institutional cohorts, studies with longer follow-up, and studies reporting location-specific functional outcomes.
RESULTS
Study selection and characteristics
A total of 28 publications were included in the final qualitative synthesis. The evidence base consisted predominantly of retrospective single-institutional and multicenter observational studies, together with systematic reviews, meta-analyses, a practice guideline, and a multimodal treatment study addressing a rare skull-base location. The included studies evaluated cavernous sinus, petroclival, perioptic, cerebellopontine angle, posterior fossa, tentorial, anterior clinoidal, tuberculum sellae, olfactory groove, foramen magnum, and jugular foramen meningiomas. Two additional studies specifically addressed hypofractionated or fractionated radiosurgery for large skull-base meningiomas. Most original studies included radiologically presumed or histologically confirmed World Health Organization (WHO) grade 1 meningiomas and evaluated SRS either as primary treatment or as adjuvant treatment for residual or recurrent disease.
Cavernous sinus meningiomas
Cavernous sinus meningiomas represented the most extensively studied subgroup. Because complete microsurgical removal may result in injury to the ocular motor nerves, trigeminal divisions, or internal carotid artery, SRS was frequently used as primary treatment for small- to moderate-sized tumors and as adjuvant treatment for residual intracavernous disease. In an early long-term series, Lee et al. [7] demonstrated durable tumor control after SRS, particularly in tumors measuring approximately 3 cm or less in diameter or 15 cm3 or less in volume. Most patients received single-fraction treatment with marginal doses within the range commonly used for benign meningiomas, and neurological deterioration was uncommon [7].
The International Stereotactic Radiosurgery Society systematic review concluded that SRS provides high long-term tumor-control rates and a relatively low incidence of permanent morbidity in WHO grade 1 cavernous sinus meningiomas. The available evidence supported its use as either primary treatment or postoperative treatment, particularly when complete microsurgical removal would carry a high risk of cranial nerve dysfunction [4]. A subsequent multicenter study including more than 1,000 patients confirmed durable radiological control and a low rate of permanent treatment-related morbidity. Small- to medium-sized tumors were considered the most favorable targets, although larger tumors confined mainly to the cavernous sinus were also treated successfully in selected patients [8].
Single-fraction SRS, typically using a marginal dose of approximately 12–14 Gy, was the predominant treatment for tumors without substantial optic pathway exposure. Hypofractionated or conventionally fractionated stereotactic treatment was more frequently considered when the tumor broadly contacted the optic apparatus or had a large extracavernous component. Progressive visual loss, substantial temporal lobe or brainstem compression, and extensive extracavernous growth were generally regarded as reasons to consider surgical decompression, followed by SRS to the residual intracavernous component.
Petroclival meningiomas
SRS was used for petroclival meningiomas as both primary treatment and postoperative treatment following function-preserving subtotal resection. Flannery et al. [9] reported durable long-term control and avoidance of additional microsurgical procedures in most patients treated with Gamma Knife radiosurgery. Primary SRS was principally used for relatively small tumors without a need for immediate brainstem decompression, whereas postoperative SRS was used for residual disease involving the clivus, cavernous sinus, brainstem surface, or cranial nerves [9].
In a multicenter series of 254 patients, 140 underwent primary SRS and 114 underwent SRS after resection. At follow-up, tumor volume decreased in 39%, remained stable in 52%, and increased in 9%. The reported progression-free survival rates were 97% at 3 years, 93% at 5 years, and 84% at 10 years. Smaller tumor volume was independently associated with a more favorable combined radiological and neurological outcome [5].
A systematic review and meta-analysis comparing primary and adjuvant radiosurgery found high tumor-control rates with both strategies. Primary SRS was most commonly applied to small tumors without clinically significant mass effect, whereas surgery followed by SRS was favored when brainstem decompression or tissue diagnosis was required [10]. Upfront SRS has also been reported to provide favorable control in selected asymptomatic petroclival meningiomas, further supporting observation or radiosurgery rather than immediate microsurgery for tumors without substantial compression [11].
The petroclival literature indicated that the degree of brainstem deformation, hydrocephalus, and progressive cranial neuropathy was more important than tumor size alone. Single-fraction SRS was generally used for small, noncompressive tumors, while fractionated treatment was considered for larger lesions with broad brainstem contact. Marked brainstem compression or progressive neurological dysfunction favored decompressive surgery followed by radiosurgery to the residual tumor.
Perioptic meningiomas
Perioptic meningiomas were commonly defined as lesions located within 3 mm of the optic nerve, chiasm, or optic tract. In an international multicenter study of 438 patients, the median treatment volume was approximately 8 cm3 and the median prescription dose was 12 Gy. Progression-free survival was 96% at 5 years and 89% at 10 years. Visual deterioration occurred in approximately 10% of patients. A prescription dose of at least 12 Gy was associated with improved tumor control, whereas a maximum optic apparatus dose of 10 Gy or greater and post-treatment tumor progression were associated with a higher risk of visual deterioration [12].
Direct tumor contact with the optic apparatus did not constitute an absolute contraindication to SRS in carefully selected patients. In an international multicenter study of 328 meningiomas directly contacting the optic nerve, chiasm, or tract, most tumors remained stable or decreased in size, and visual function was preserved in the large majority. Nevertheless, visual deterioration unrelated to tumor progression remained a clinically relevant risk, emphasizing the importance of optic dose limitation and long-term follow-up [13].
A systematic review and meta-analysis evaluating single-fraction and hypofractionated radiosurgery reported high tumor-control and visual-preservation rates with both techniques in selected perioptic meningiomas. Hypofractionation was particularly applicable when the desired tumor margin dose could not be delivered safely in one fraction because of broad optic contact [14]. Across the perioptic studies, treatment selection was therefore primarily determined by the feasibility of delivering an effective tumor dose while limiting optic pathway exposure. Tumors causing progressive visual deterioration through optic canal or chiasmal compression were generally considered more suitable for surgical decompression, with SRS reserved for residual disease.
Tuberculum sellae and planum sphenoidale meningiomas
Location-specific evidence for tuberculum sellae meningiomas was derived mainly from a series of 78 consecutive patients treated with Gamma Knife radiosurgery. The median target volume was 1.7 cm3, illustrating that most treated tumors were small. The reported progression-free survival rates were 100% at 1 year, 97.9% at 5 years, and 94.5% at 10 years. Both primary and postoperative SRS were used, with favorable tumor control in carefully selected patients without a need for immediate optic nerve decompression [15].
A multicenter study of sellar and parasellar meningiomas provided supporting evidence that SRS can achieve durable control while preserving endocrine and visual function in selected small tumors and postoperative residuals [16]. However, the favorable outcomes reported for tuberculum sellae tumors should be interpreted in the context of the small median treatment volume. Progressive visual decline, marked optic canal involvement, or direct mechanical compression of the optic nerve generally favored surgical decompression. SRS was most applicable to small asymptomatic tumors, patients at high surgical risk, and residual or recurrent tumors after optic nerve decompression.
Anterior clinoidal meningiomas
Anterior clinoidal meningiomas were evaluated in a consecutive series of 61 patients treated with Gamma Knife radiosurgery. The study demonstrated favorable tumor-volume control with a relatively low complication rate, supporting SRS for selected small primary tumors and postoperative residuals. Visual outcomes were influenced by the relationship between the tumor and optic apparatus, as well as by pre-existing visual function [17].
A subsequent multi-institutional study similarly demonstrated durable tumor control after SRS for clinoid meningiomas. Higher prescription doses were associated with tumor regression, although dose delivery was frequently limited by optic pathway proximity. Most patients maintained stable visual function, but the findings reflected careful selection and treatment planning [18].
For anterior clinoidal tumors, SRS was most often applied to small primary tumors without progressive visual impairment or to residual tumors after surgical decompression. The cavernous sinus component of a clinoidal meningioma was particularly suitable for postoperative SRS, whereas progressive visual loss associated with optic canal invasion generally required decompression before radiosurgical treatment.
Cerebellopontine angle and posterior petrous meningiomas
In a series of 74 patients with cerebellopontine angle meningiomas, the median tumor volume was 3.0 cm3 and the median marginal dose was 13 Gy. SRS provided a high rate of radiological control with a relatively low incidence of adverse radiation effects, supporting its use for small- to medium-sized tumors without substantial pontine compression or hydrocephalus [19].
A systematic review and meta-analysis confirmed high tumor-control rates and low rates of serious treatment-related morbidity following SRS for cerebellopontine angle meningiomas [20]. Most included tumors were relatively small, and the findings could not be directly generalized to large tumors causing marked brainstem compression.
Treatment planning in this location required consideration of brainstem contact, pre-treatment hearing, cochlear dose, internal auditory canal extension, and the functional status of the trigeminal, facial, and vestibulocochlear nerves. Single-fraction SRS was typically used for limited-volume lesions, while fractionation was considered when the tumor broadly contacted the brainstem or cochlea. Large symptomatic tumors associated with hydrocephalus or significant brainstem deformation generally required surgical decompression, with SRS subsequently used for residual petrous or cranial nerve–adherent tumor.
Posterior fossa meningiomas
The largest multicenter posterior fossa study included 675 patients treated with Gamma Knife radiosurgery. The mean tumor volume was approximately 6.5 cm3 and the median marginal dose was approximately 13.6 Gy. Overall tumor control was achieved in 91.2% of patients, with actuarial control rates of 95% at 3 years, 92% at 5 years, and 81% at 10 years. Increasing tumor volume was associated with both radiological progression and neurological decline [21].
Long-term volumetric evaluation of WHO grade 1 posterior fossa meningiomas further suggested that adequate marginal dosing was important for durable control. Patibandla et al. [22] reported superior long-term progression-free survival in patients receiving marginal doses of 13–15 Gy compared with those receiving 12 Gy or less. The authors also found that volumetric response during the initial years after SRS was informative for subsequent long-term control [22].
These findings supported SRS for relatively small posterior fossa meningiomas without clinically significant brainstem compression. When proximity to the brainstem or other critical structures precluded delivery of an adequate single-fraction dose, fractionated treatment or surgical volume reduction was considered.
Tentorial meningiomas
Early location-specific studies established that tentorial meningiomas could be treated effectively with SRS in selected patients. Muthukumar et al. [23] reported favorable tumor control after radiosurgery for primary and postoperative tentorial meningiomas, although the study predated contemporary volumetric planning and dose constraints.
A later 22-year institutional experience evaluated long-term outcomes following Gamma Knife radiosurgery for tentorial meningiomas. The study included tumors arising from lateral, medial, and incisural portions of the tentorium and demonstrated durable tumor control in the majority of patients [24].
Lateral tentorial meningiomas generally provided more favorable radiosurgical anatomy than medial or incisural tumors. Medial and incisural lesions required particular attention to the midbrain, ocular motor nerves, temporal lobe, and deep venous structures. Single-fraction SRS was primarily used for small circumscribed lesions without substantial edema or mass effect, while larger tumors or tumors broadly contacting the midbrain were more suitable for fractionated treatment or surgical decompression.
Olfactory groove meningiomas
In a series of 41 patients with olfactory groove meningiomas, the median tumor volume was 8.5 cm3 and the mean marginal dose was approximately 13 Gy. Tumor volume decreased in 32%, remained stable in 63%, and increased in 5%, corresponding to an overall tumor-control rate of approximately 95%. No patient reported deterioration of subjective olfactory function after SRS, although symptomatic adverse radiation effects occurred in a small proportion of patients [25].
The reported SRS cohorts mainly included small- to moderate-sized primary tumors or postoperative residual and recurrent tumors without substantial frontal lobe compression. Therefore, the favorable results should not be extrapolated to very large olfactory groove meningiomas presenting with marked edema, visual compression, or cognitive and behavioral symptoms. In such cases, surgical decompression remained the preferred initial treatment.
Foramen magnum meningiomas
Foramen magnum meningiomas were evaluated in several location-specific studies. An international multicenter study demonstrated that SRS provided favorable tumor control and neurological preservation in selected patients, particularly those with small primary tumors or postoperative residual disease without substantial medullary compression [6].
In a long-term Gamma Knife series of 37 patients, tumor volume decreased in 35.1%, remained stable in 62.2%, and increased in 2.7%, yielding a tumor-control rate of 97.3%. No patient experienced worsening of pre-treatment symptoms during follow-up [26].
A single-center study and systematic review reported a weighted median target volume of 2.9 cm3 and a weighted median marginal dose of 12.9 Gy. Approximately 91.5% of patients underwent single-fraction treatment, with reported local control and clinical stability rates of 97.0% and 98.8%, respectively [27].
The small median treatment volume across these studies indicates that the evidence primarily supports SRS for limited-volume tumors without marked deformation of the medulla or upper cervical spinal cord. Progressive myelopathy, long-tract signs, dysphagia, or substantial medullary compression generally favored surgical decompression.
Jugular foramen meningiomas
Location-specific evidence for SRS of jugular foramen meningiomas was limited. Most available reports included small multimodal cohorts or combined these tumors with other posterior fossa meningiomas. A function-preserving multimodal treatment series described the use of limited resection or decompression followed by SRS for residual disease, with the aim of minimizing additional lower cranial nerve morbidity [28]. The available evidence suggested that SRS may be considered for small- to moderate-sized primary or residual tumors in patients with stable or mild lower cranial nerve deficits. This approach is attractive because aggressive microsurgery may produce additional glossopharyngeal, vagal, or accessory nerve dysfunction. However, progressive dysphagia, aspiration, worsening lower cranial nerve palsy, or substantial brainstem compression generally required surgical decompression. Owing to the rarity of these tumors and the absence of large SRS-only series, uniform location-specific dose or volume thresholds could not be established.
Large skull-base meningiomas and fractionated stereotactic treatment
Increasing tumor volume was consistently associated with less favorable outcomes after single-fraction SRS across skull-base locations. Nevertheless, large volume did not constitute an absolute contraindication to stereotactic treatment when immediate decompression was not required.
Park et al. [29] evaluated fractionated Gamma Knife radiosurgery as initial treatment for large skull-base meningiomas, generally defined as tumors measuring at least 10 cm3. The mean tumor volume was approximately 21 cm3, and treatment was commonly delivered in three fractions with a cumulative marginal dose of approximately 18 Gy. The study demonstrated the feasibility of fractionated Gamma Knife treatment for selected large tumors located near critical neurovascular structures [29].
Oh et al. [30] evaluated hypofractionated SRS for tumors larger than 10 cm3. The median tumor volume was approximately 18.9 cm3, and treatment was generally delivered in three to five fractions with a median cumulative dose of approximately 27.8 Gy. Tumor control was achieved in approximately 90% of patients at intermediate-term follow-up [30].
These findings supported fractionated stereotactic treatment for large but noncompressive skull-base meningiomas, particularly in elderly or medically inoperable patients and when a sufficient single-fraction margin dose could not be delivered safely. However, the studies involved selected patients and did not establish fractionated SRS as a substitute for surgery in tumors causing marked brainstem compression, optic pathway compression, hydrocephalus, or rapidly progressive neurological deficits.
Overall location-specific findings
Across the included studies, SRS achieved high rates of long-term tumor control for appropriately selected skull-base meningiomas. Cavernous sinus meningiomas had the broadest indication for primary and postoperative SRS because aggressive microsurgical removal carries substantial cranial nerve and vascular risks. Petroclival, cerebellopontine angle, posterior fossa, tentorial, and foramen magnum meningiomas required greater emphasis on brainstem, medullary, or spinal cord compression, and surgery remained important when immediate decompression was required.
For perioptic, tuberculum sellae, and anterior clinoidal meningiomas, the feasibility of delivering an effective tumor dose while maintaining optic pathway tolerance was a central determinant of treatment selection. Olfactory groove meningiomas showed favorable tumor and olfactory outcomes after SRS in selected patients without marked frontal lobe mass effect. Evidence regarding jugular foramen meningiomas remained limited and principally supported a multimodal, function-preserving strategy.
Smaller tumor volume, absence of clinically significant mass effect, adequate prescription dose, and preserved pre-treatment neurological function were repeatedly associated with favorable outcomes. Hypofractionated or fractionated treatment extended the use of stereotactic radiation to selected large or critically located tumors, but surgical decompression remained the preferred initial treatment for lesions producing major neural compression or rapidly progressive functional deterioration. The principal location-specific indications, treatment strategies, outcomes, and situations favoring surgery are summarized in Table 1.
DISCUSSION
The present review demonstrates that SRS provides durable tumor control with acceptable neurological morbidity in appropriately selected patients with skull-base meningiomas. However, its clinical role is not uniform across all skull-base locations. The most favorable results were generally reported in patients with relatively limited tumor volumes, preserved neurological function, and no requirement for immediate decompression. Cavernous sinus meningiomas had the most established indication for primary or postoperative SRS, whereas treatment decisions for petroclival, posterior fossa, perioptic, and foramen magnum meningiomas were more strongly influenced by compression of the brainstem, optic apparatus, medulla, or spinal cord. These findings suggest that anatomical relationships and functional status should be considered together with tumor volume when selecting patients for SRS.
Stereotactic radiosurgery as a function-preserving treatment
The management of skull-base meningiomas has progressively shifted from radical removal toward long-term tumor control with preservation of neurological function. Although gross-total resection may offer definitive treatment, aggressive dissection around the cranial nerves, major arteries, venous structures, brainstem, and optic pathways can cause substantial and sometimes permanent morbidity. This concern is particularly relevant for tumors involving the cavernous sinus, petroclival region, anterior clinoid, tentorial incisura, and lower skull base.
In this context, SRS should not be regarded solely as an alternative for elderly or medically inoperable patients. It has become an integral component of function-preserving management. Primary SRS can provide long-term control of selected small- to moderate-sized tumors, while postoperative SRS allows surgeons to leave tumor intentionally along critical neurovascular structures rather than pursuing complete removal at the cost of functional deterioration. The long-term cavernous sinus experience illustrates this principle particularly well, as durable control has been achieved without exposing patients to the neurological risks associated with aggressive intracavernous dissection [4,7].
This approach is also applicable to petroclival meningiomas. Complete removal may require extensive dissection from the brainstem, basilar artery, perforating vessels, and multiple cranial nerves. Long-term studies have shown that SRS can avoid initial or additional microsurgery in many patients with smaller tumors, while postoperative SRS provides a means of controlling residual disease after function-preserving decompression [5,9].
Location-specific roles of stereotactic radiosurgery
Among the anatomical subgroups evaluated, cavernous sinus meningiomas appear to have the broadest indication for radiosurgical treatment. Complete resection of the intracavernous component is frequently limited by its relationship to the internal carotid artery and cranial nerves III, IV, V, and VI. Consequently, primary SRS for a radiographically typical, limited-volume lesion or postoperative SRS for residual intracavernous disease is often preferable to aggressive resection. The favorable results reported in large multicenter cohorts support this strategy. However, the radiosurgical advantage becomes less clear when the tumor extends substantially beyond the cavernous sinus and produces optic pathway, temporal lobe, or brainstem compression. In such cases, decompression or fractionated treatment may be required rather than single-fraction SRS alone.
The treatment of petroclival meningiomas differs because relatively small increases in tumor volume may produce clinically important brainstem displacement or cranial nerve dysfunction. Primary SRS can provide durable control of small, noncompressive tumors, including selected asymptomatic lesions, but it does not provide immediate relief of mass effect. In patients with marked brainstem deformation, hydrocephalus, or progressive neurological deficits, surgical decompression remains necessary. SRS is then particularly useful for controlling residual tumor attached to the brainstem, clivus, cavernous sinus, or cranial nerves. The available meta-analysis supports both primary and adjuvant SRS but also indicates that primary radiosurgery is generally applied to patients with smaller and less symptomatic tumors [10].
For perioptic, tuberculum sellae, and anterior clinoidal meningiomas, the principal issue is not tumor volume alone but whether an effective marginal dose can be delivered while maintaining acceptable exposure of the optic apparatus. The multicenter perioptic series demonstrated that long-term control could be achieved even when tumors were located within 3 mm of the optic pathways. However, a maximum optic apparatus dose of at least 10 Gy and subsequent tumor progression were associated with increased visual deterioration, whereas a prescription dose of at least 12 Gy was associated with improved tumor control [12]. These findings illustrate the competing requirements of adequate tumor dosing and visual preservation. Direct optic contact does not necessarily preclude radiosurgery, but broad contact or circumferential involvement may favor hypofractionated treatment. When visual deterioration results from mechanical optic canal or chiasmal compression, surgery remains necessary because SRS cannot provide immediate decompression. The favorable results reported for tuberculum sellae meningiomas should also be interpreted in the context of the small median tumor volume in the published cohort [15].
Cerebellopontine angle, posterior petrous, tentorial, and other posterior fossa meningiomas present a different set of constraints. In these locations, even histologically benign tumors may cause clinically important compression of the brainstem, cerebellum, or cranial nerves within a confined anatomical space. The largest posterior fossa multicenter study demonstrated high long-term tumor control, but increasing tumor volume was associated with both progression and neurological deterioration [21]. Long-term volumetric analysis also suggested that adequate marginal dose is important for sustained control, emphasizing that a low single-fraction dose selected solely to protect the brainstem may compromise tumor control [22].
Foramen magnum meningiomas illustrate the importance of differentiating anatomical contact from clinically significant compression. Published SRS cohorts predominantly consisted of small tumors, with favorable local control and neurological stability. These findings support SRS for limited primary tumors and postoperative residuals without major medullary or upper cervical cord deformation. They should not, however, be extrapolated to patients with progressive myelopathy, long-tract signs, dysphagia, or significant cervicomedullary compression, in whom decompression remains the primary therapeutic objective [6].
Olfactory groove meningiomas also require careful interpretation. SRS can provide durable tumor control and may preserve olfactory function in selected patients, particularly those with small primary tumors or residual and recurrent disease. Nevertheless, many surgically treated olfactory groove meningiomas present only after becoming large enough to cause frontal lobe compression, edema, visual symptoms, or cognitive and behavioral changes. The favorable radiosurgical outcomes reported in selected cohorts should therefore not be generalized to large symptomatic lesions requiring decompression.
Tumor volume and mass effect
Tumor volume was repeatedly associated with outcome across the included studies, but the available evidence does not support a single size threshold applicable to every skull-base location. A tumor volume that is well tolerated within the cavernous sinus may cause substantial neurological dysfunction when located at the petroclival junction, cerebellopontine angle, tentorial incisura, or foramen magnum. Similarly, a relatively small perioptic tumor may be unsuitable for single-fraction treatment if its geometry prevents adequate dosing without excessive optic pathway exposure.
Accordingly, tumor volume should be interpreted together with the direction of growth, degree of neural compression, pre-existing neurological deficits, surrounding edema, and the feasibility of adequate dose delivery. The relationship between size and outcome reported in the petroclival and posterior fossa series likely reflects not only the larger radiation volume but also greater distortion of adjacent cranial nerves and the brainstem [5,21].
The inability to define a universal cutoff should not be regarded as a weakness of SRS but rather as a reflection of the anatomical diversity of skull-base meningiomas. The current evidence supports individualized selection rather than a simple diameter- or volume-based rule. In particular, the indication for surgery should be driven primarily by the need for decompression or diagnostic clarification, whereas the indication for SRS should be based on the likelihood of achieving durable control without exceeding the tolerance of adjacent structures.
Single-fraction and fractionated treatment
Single-fraction SRS has the largest evidence base for benign skull-base meningiomas and is commonly used for limited-volume tumors that can receive an adequate marginal dose while respecting the optic apparatus and brainstem. However, the therapeutic window becomes narrower as tumor volume increases or as the lesion broadly contacts critical structures. Fractionated or hypofractionated stereotactic treatment may reduce the biological effect on adjacent neural tissues while allowing treatment of a larger target volume.
The systematic review of perioptic meningiomas found favorable control and visual outcomes with both single-fraction and hypofractionated approaches, supporting fractionation when safe single-fraction dosing is not feasible [14]. Large skull-base meningioma studies have likewise demonstrated that fractionated Gamma Knife or hypofractionated SRS can achieve acceptable intermediate-term control in selected patients with tumors larger than those typically treated in a single fraction [29,30].
Nevertheless, these studies largely involved carefully selected patients without an urgent need for decompression. Fractionation expands the applicability of stereotactic treatment but does not eliminate the need for surgery in patients with severe brainstem compression, hydrocephalus, rapidly progressive visual loss, myelopathy, or other neurological deterioration caused by mass effect. Moreover, direct comparisons between single-fraction and fractionated regimens remain limited, and the optimal number of fractions and total dose have not been standardized for each skull-base location.
Primary stereotactic radiosurgery and surgery followed by stereotactic radiosurgery
Primary SRS and microsurgery should not be viewed as competing strategies. Their roles are complementary and depend on the therapeutic objective. Primary SRS is most appropriate for radiographically typical, small- to moderate-sized tumors without clinically significant mass effect, particularly when the risks of surgery exceed the anticipated benefits of tissue removal. Surgery remains important when decompression, pathological diagnosis, or rapid restoration of neural function is required.
For surgically challenging skull-base tumors, maximal safe resection followed by selective SRS may offer a more favorable balance than gross-total resection at any cost. This concept is particularly relevant for petroclival and cavernous sinus meningiomas. Long-term surgical studies have suggested that optimal subtotal resection followed by postoperative radiation or SRS may provide tumor control comparable to more radical surgery while reducing treatment-related morbidity [31].
The timing of postoperative SRS remains less clearly defined. Immediate adjuvant treatment may control a small and well-defined residual tumor before further growth, whereas observation avoids unnecessary irradiation of residual lesions that may remain stable for years. The choice should therefore consider residual tumor volume, anatomical location, documented growth, histological grade, patient age, and feasibility of reliable imaging surveillance. Current evidence does not support mandatory immediate SRS for every residual WHO grade 1 skull-base meningioma.
Interpretation of neurological outcomes
Radiological tumor control and functional success should be considered separately. Stabilization of tumor size may represent a successful outcome when further growth would otherwise threaten vision, hearing, swallowing, or brainstem function. Conversely, radiographic control does not necessarily result in recovery of a pre-existing cranial nerve deficit, especially when the deficit has been prolonged or results from irreversible neural injury.
Future studies should therefore distinguish improvement, stability, and deterioration for individual cranial nerves rather than reporting a composite neurological outcome. Standardized assessment of visual acuity and fields, ocular motor function, trigeminal symptoms, hearing, facial nerve function, swallowing, and patient-reported quality of life would improve comparisons between treatment modalities. This is particularly important because the primary clinical benefit of SRS for many skull-base meningiomas is preservation of existing function rather than tumor shrinkage.
Limitations of the available evidence
The present findings should be interpreted in light of several limitations of the underlying literature. Most original studies were retrospective, and the indications for primary SRS, postoperative SRS, fractionated treatment, or surgery were determined by institutional practice and patient selection rather than random allocation. Consequently, patients treated with primary SRS generally had smaller, less symptomatic, and less compressive tumors than those referred for surgery. Direct comparisons between surgery and SRS are therefore vulnerable to substantial selection bias.
Outcome definitions also varied considerably. Tumor progression was assessed using changes in maximum diameter, two-dimensional measurements, volumetric analysis, or the requirement for salvage treatment. Cranial nerve outcomes and adverse radiation effects were not reported uniformly, and follow-up duration differed among studies. Because benign meningiomas may progress many years after treatment, studies with short or intermediate follow-up may overestimate durable control.
Histological confirmation was unavailable in many patients treated with primary SRS, although most lesions had imaging features considered typical of benign meningioma. In addition, multiple publications originated from high-volume radiosurgical institutions or multicenter consortia, creating a potential for overlapping patient cohorts. Location-specific evidence remained limited for uncommon tumors, particularly jugular foramen meningiomas, and some recommendations for these lesions were derived from small series or broader posterior fossa cohorts.
This review also has methodological limitations. The included studies were heterogeneous in design, anatomical classification, treatment platform, tumor volume, prescription dose, and follow-up, precluding meaningful quantitative pooling. The narrative synthesis incorporated original studies, systematic reviews, and selected guideline or multimodal-treatment reports, which differ in their level and purpose of evidence. The restriction to English-language full-text publications may also have resulted in language bias. Although AI-assisted tools were used during preliminary record organization and screening, final study eligibility and inclusion were independently verified by two reviewers.
Future directions
Prospective randomized trials are unlikely to be feasible for many skull-base meningioma subgroups because of their rarity, slow growth, anatomical heterogeneity, and strong treatment-selection preferences. Prospective multicenter registries may therefore provide the most practical means of improving the evidence base. Such registries should use standardized volumetric measurements, anatomical classifications, cranial nerve assessments, and patient-reported outcomes.
Future studies should also clarify the relative benefits of immediate versus delayed postoperative SRS and directly compare single-fraction and hypofractionated treatment for perioptic and larger skull-base tumors. Longer follow-up is required to evaluate late progression, delayed cranial neuropathy, vascular effects, hypopituitarism, and secondary radiation-related neoplasms. Integration of molecular classification and radiomic features may eventually improve the prediction of growth and radiosurgical response.
Importantly, future studies should determine whether location-specific anatomical variables, including neural compression, compartmental extension, and target–organ-at-risk geometry, predict treatment suitability more accurately than tumor size alone. Until such evidence is available, treatment should remain individualized and based on the combined assessment of anatomical location, tumor volume, neurological status, growth behavior, and the need for decompression.
Conclusion
SRS provides durable tumor control and preserves neurological function in appropriately selected patients with skull-base meningiomas. Its strongest indications are limited-volume tumors without a requirement for immediate decompression and residual disease intentionally left within surgically hazardous compartments. The role of SRS should be individualized according to anatomical location and critical-structure relationships and integrated with microsurgery as part of a function-preserving treatment strategy rather than regarded as a competing therapeutic modality.
Notes
CONFLICTS OF INTEREST
Min Ho Lee is an Editor of this journal and was not involved in the review process or editorial decision-making for this manuscript. No other potential conflict of interest relevant to this article was reported.
ACKNOWLEDGEMENTS
AI-assisted tools were used to organize the PubMed search results and support preliminary title and abstract screening. Final full-text eligibility assessment and selection of the included publications were independently verified by two reviewers (Y.Y. and M.H.L.), and all final inclusion decisions were made by the authors. The AI-assisted tools were not used to independently determine study eligibility or interpret the study findings. The authors reviewed and verified all AI-assisted outputs and take full responsibility for the accuracy and integrity of this review.
SUPPLEMENTARY MATERIAL
Detailed PubMed Search Strategy
